Your browser is no longer supported. Please, upgrade your browser.
Settings
BPTH Bio-Path Holdings, Inc. daily Stock Chart
BPTH [NASD]
Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-5.34 Insider Own5.62% Shs Outstand2.81M Perf Week9.66%
Market Cap22.34M Forward P/E- EPS next Y-2.57 Insider Trans0.00% Shs Float2.73M Perf Month-29.08%
Income-8.10M PEG- EPS next Q-0.69 Inst Own25.90% Short Float3.03% Perf Quarter-29.08%
Sales- P/S- EPS this Y10.10% Inst Trans-11.33% Short Ratio0.69 Perf Half Y-38.42%
Book/sh5.58 P/B1.42 EPS next Y18.90% ROA-53.40% Target Price25.00 Perf Year20.53%
Cash/sh5.48 P/C1.45 EPS next 5Y- ROE-58.70% 52W Range1.61 - 73.52 Perf YTD127.14%
Dividend- P/FCF- EPS past 5Y-9.50% ROI- 52W High-89.19% Beta3.05
Dividend %- Quick Ratio13.90 Sales past 5Y- Gross Margin- 52W Low393.79% ATR0.74
Employees9 Current Ratio13.90 Sales Q/Q- Oper. Margin- RSI (14)42.08 Volatility8.55% 10.07%
OptionableNo Debt/Eq0.00 EPS Q/Q85.50% Profit Margin- Rel Volume0.94 Prev Close7.72
ShortableYes LT Debt/Eq0.00 EarningsNov 15 BMO Payout- Avg Volume120.77K Price7.95
Recom- SMA20-11.62% SMA50-20.11% SMA200-41.77% Volume112,714 Change2.98%
Nov-13-17Reiterated H.C. Wainwright Buy $4.50 → $1.50
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
Dec-06-19 09:25AM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq: BPTH) ACCESSWIRE
Dec-05-19 09:42PM  Edited Transcript of BPTH earnings conference call or presentation 15-Nov-19 1:30pm GMT Thomson Reuters StreetEvents -6.42%
Dec-04-19 12:00PM  Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know Zacks +15.55%
Nov-26-19 08:00AM  Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia GlobeNewswire -5.56%
Nov-25-19 02:11PM  Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
Nov-21-19 11:30AM  Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -22.24%
08:00AM  Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 GlobeNewswire
Nov-15-19 07:00AM  Bio-Path Holdings Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-08-19 08:00AM  Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019 GlobeNewswire
Oct-29-19 06:47AM  Investors Who Bought Bio-Path Holdings (NASDAQ:BPTH) Shares Five Years Ago Are Now Down 98% Simply Wall St.
Oct-16-19 02:29PM  Houston biotech co. avoids stock exchange delisting amid board shakeup American City Business Journals
Oct-15-19 08:00AM  Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors GlobeNewswire
Sep-25-19 08:00AM  Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent GlobeNewswire
Sep-14-19 09:36AM  Is Bio-Path Holdings, Inc. (NASDAQ:BPTH) Excessively Paying Its CEO? Simply Wall St.
Sep-04-19 01:10AM  Edited Transcript of BPTH earnings conference call or presentation 15-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Sep-03-19 04:01PM  Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-26-19 07:00AM  Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia GlobeNewswire
Aug-15-19 07:00AM  Bio-Path Holdings Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-08-19 04:01PM  Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019 GlobeNewswire
Jul-17-19 11:39AM  A Look At Benzinga Pro's Most-Searched Tickers For July 17, 2019 Benzinga -12.64%
Jul-16-19 08:18AM  What Kind Of Shareholder Appears On The Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Shareholder Register? Simply Wall St. +33.10%
Jun-04-19 11:51AM  Edited Transcript of BPTH earnings conference call or presentation 16-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 07:05AM  Bio-Path: 1Q Earnings Snapshot Associated Press -5.58%
07:00AM  Bio-Path Holdings Reports First Quarter 2019 Financial Results GlobeNewswire
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
May-15-19 08:16AM  Easy Come, Easy Go: How Bio-Path Holdings (NASDAQ:BPTH) Shareholders Torched 97% Of Their Cash Simply Wall St.
May-10-19 04:01PM  Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019 GlobeNewswire
Apr-29-19 09:00AM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
Apr-15-19 04:33PM  How This Highly Rated Biotech Stock Added To Its Meteoric Run Investor's Business Daily +32.52%
01:01PM  Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today InvestorPlace
10:46AM  Bio-Path's stock rockets after withdrawal of stock offering MarketWatch
Apr-03-19 08:00AM  Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace -14.05%
Mar-20-19 09:15AM  Bio-Path Holdings Reports Full Year 2018 Financial Results GlobeNewswire -14.68%
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-15-19 04:01PM  Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019 GlobeNewswire +7.03%
Mar-14-19 03:10PM  Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock Business Wire -11.53%
Mar-12-19 09:15AM  Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock GlobeNewswire +8.29%
Mar-08-19 01:25PM  The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands Benzinga -45.96%
07:30AM  The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant ACCESSWIRE
Mar-07-19 11:55AM  Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker Bloomberg +223.29%
10:35AM  UPDATE: Bio-Path stock gains another 130% on Thursday MarketWatch
Mar-06-19 02:35PM  Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising ACCESSWIRE +160.46%
01:27PM  Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today InvestorPlace
10:00AM  Under the Radar Cannabis Stock-THC Therapeutics, Inc. ACCESSWIRE
08:00AM  Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia GlobeNewswire
Mar-04-19 06:10AM  Is Bio-Path Holdings, Inc.s (NASDAQ:BPTH) CEO Pay Justified? Simply Wall St. -28.76%
Feb-28-19 08:00AM  Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting GlobeNewswire +28.71%
Jan-24-19 04:30PM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
Jan-23-19 04:01PM  Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market GlobeNewswire +10.50%
Jan-18-19 12:31PM  Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -30.56%
08:00AM  Bio-Path Holdings Announces 1-for-20 Reverse Stock Split GlobeNewswire
Jan-17-19 04:07PM  Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-16-19 08:24AM  The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen Benzinga
Jan-14-19 10:23PM  Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.96%
04:01PM  Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Dec-27-18 08:49AM  Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook GlobeNewswire
Dec-26-18 09:47AM  Could Bio-Path Holdings, Inc.s (NASDAQ:BPTH) Investor Composition Influence The Stock Price? Simply Wall St. -24.73%
Dec-03-18 07:22AM  Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting GlobeNewswire -22.11%
Nov-25-18 09:41AM  The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings Benzinga
Nov-15-18 07:20AM  Bio-Path: 3Q Earnings Snapshot Associated Press
07:00AM  Bio-Path Holdings Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-08-18 04:01PM  Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018 GlobeNewswire
Nov-01-18 09:05AM  Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting GlobeNewswire +7.47%
Oct-09-18 01:11PM  What does Bio-Path Holdings Incs (NASDAQ:BPTH) Balance Sheet Tell Us About Its Future? Simply Wall St.
Sep-25-18 04:01PM  Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering GlobeNewswire
Sep-21-18 06:30AM  Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering GlobeNewswire -36.46%
Aug-29-18 08:00AM  Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire -6.00%
Aug-27-18 07:30AM  Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia GlobeNewswire
Aug-16-18 10:26AM  Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board GlobeNewswire -5.33%
Aug-15-18 07:05AM  Bio-Path: 2Q Earnings Snapshot Associated Press +6.38%
07:00AM  Bio-Path Holdings Reports Second Quarter 2018 Financial Results GlobeNewswire
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-18 09:15AM  Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018 GlobeNewswire +5.82%
Jun-26-18 08:00AM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
May-16-18 08:11AM  With A -19.42% Earnings Drop, Is Bio-Path Holdings Incs (NASDAQ:BPTH) A Concern? Simply Wall St.
07:08AM  Bio-Path: 1Q Earnings Snapshot Associated Press
07:00AM  Bio-Path Holdings Reports First Quarter 2018 Financial Results GlobeNewswire
May-10-18 08:00AM  Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board GlobeNewswire
May-09-18 08:00AM  Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018 GlobeNewswire
Apr-18-18 04:01PM  Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-09-18 07:20AM  Wired News EMA Completed Validation of MAA for Aradigms Linhaliq in Non-Cystic Fibrosis Bronchiectasis ACCESSWIRE -5.21%
Apr-04-18 11:15AM  Bio-Path Leukemia Combo Study Shows Positive Early Data Zacks -9.50%
Apr-03-18 12:03PM  Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today InvestorPlace +24.86%
08:35AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:30AM  Bio-Path Holdings Reports Full Year 2017 Financial Results GlobeNewswire
07:15AM  Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML) GlobeNewswire
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-29-18 08:00AM  Bio-Path Holdings Announces Publication in The Lancet Haematology GlobeNewswire
Mar-27-18 04:15PM  Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018 GlobeNewswire
Mar-15-18 07:00AM  Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting GlobeNewswire +7.02%
Mar-06-18 07:00AM  Bio-Path Holdings to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-09-18 07:00AM  Bio-Path Holdings Announces 1-for-10 Reverse Stock Split GlobeNewswire
Feb-05-18 04:01PM  Bio-Path Holdings to Present at the BIO CEO & Investor Conference GlobeNewswire
08:00AM  Bio-Path Holdings Appoints Paul Aubert to its Board of Directors GlobeNewswire
Dec-29-17 04:01PM  Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook GlobeNewswire
Dec-15-17 04:30PM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
Nov-13-17 07:20AM  Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business ACCESSWIRE
Nov-10-17 06:25AM  Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio? Simply Wall St.
Nov-09-17 05:11PM  Bio-Path reports 3Q loss Associated Press
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLC10% OwnerJan 18Sale2.6664,457171,643129,298Jan 23 06:15 PM